Lactobacillus plantarum strain GB104 and composition containing same for preventing or treating cancer

Lactobacillus plantarum strain GB104 addresses the limitations of existing anticancer drugs by enhancing immune cell activity to inhibit tumor growth and formation, providing a promising treatment and prevention approach for colorectal cancer.

JP7594826B2Active Publication Date: 2024-12-05GI BIOME INC
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2023549033
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2021-03-22
Filing Date
2022-03-21
Publication Date
2024-12-05
Estimated Expiration
2042-03-21

AI Technical Summary

Technical Problem

Current anticancer drugs for colorectal cancer cause significant side effects and have not achieved commercial success, necessitating the development of a new strain with superior anti-cancer efficacy.

Method used

The use of Lactobacillus plantarum strain GB104 (accession number: KCTC 14107BP) as an active ingredient in pharmaceutical, food, and feed compositions to inhibit tumor formation and growth by enhancing immune cell activity, particularly increasing INF-γ and granzyme B production.

Benefits of technology

Lactobacillus plantarum strain GB104 effectively inhibits tumor formation and growth in cancer cell lines and animal models by stimulating immune cells, offering a potential treatment and prevention strategy with reduced side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007594826000002
    Figure 0007594826000002
  • Figure 0007594826000003
    Figure 0007594826000003
  • Figure 0007594826000004
    Figure 0007594826000004
Patent Text Reader

Abstract

The present invention relates to Lactobacillus plantarum strain GB104 (Accession Number: KCTC 14107BP) and a composition for preventing or treating cancer containing it as an active ingredient. The Lactobacillus plantarum strain GB104 according to the present invention can increase the production of INF-γ and granzyme B, and activate immune cells such as cytotoxic T cells and NK cells, thereby ultimately inhibiting the formation and growth of tumors. Therefore, a composition containing the Lactobacillus plantarum strain GB104 of the present invention as an active ingredient can increase immune activity in the body, and therefore can be effectively utilized for the treatment of cancer diseases, and is highly industrially applicable.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to Lactobacillus plantarum strain GB104 (accession number: KCTC 14107BP) and a composition for preventing or treating cancer containing the same as an active ingredient. [Background technology]

[0002] Globally, cancer is considered one of the major health problems. Among cancers, colorectal cancer is the fourth most common malignant tumor and the third leading cause of cancer deaths worldwide. Statistics on colorectal cancer in Korea show that it was not a common disease before the 1970s, but the incidence of colorectal cancer has gradually increased as diet has become more westernized in modern times. Currently, surgery is the most effective treatment method for colorectal cancer as well as other digestive system cancers. The survival rate for early stage 1 to stage 3 ranges from 70 to 90%, but the survival rate drops sharply to 15% at late stage 4.

[0003] Many anticancer drugs have been clinically developed for the treatment of colon cancer, but their long-term use causes many side effects.For example, it has been reported that fluorouracil causes neutropenia, stomatitis and diarrhea, irinotecan causes bone marrow suppression, nausea and alopecia, and oxaliplatin causes paresthesia and renal dysfunction.In this situation, there is an urgent need to create anticancer substances that can contribute to improving human health, improving healthy life quality, and promoting human happiness by enabling early prevention and treatment of cancer.

[0004] On the other hand, lactic acid bacteria are widely distributed in the oral cavity, intestines, vagina and feces of humans and animals, as well as in fermented foods such as kimchi, and are closely related to the health of humans and animals. Lactic acid bacteria exhibit various health-promoting effects, such as intestinal regulation, inhibition of harmful bacteria, immunoregulation, lowering of blood cholesterol and anti-cancer effects.

[0005] Currently, Korean Patent Application Publication No. 10-2015-0068061 discloses the anti-cancer activity of Lactobacillus plantarum PNU (KCCM11352P) or Lactobacillus mesenteroides PNU (KCCM11353P), and Korean Patent Registration No. 10-1287120 discloses a pharmaceutical composition for treating cancer containing Lactobacillus plantarum DSR CK10 (Accession No.: KFCC-11433P) or Lactobacillus plantarum DSR M2 (Accession No.: KFCC-11432P) as an active ingredient. However, the effect has not reached the level of commercial success.

[0006] Therefore, there is a need for continued research into new strains with superior anti-cancer effects. Summary of the Invention [Problem to be solved by the invention]

[0007] Therefore, the present inventors have conducted research to develop a new strain with excellent anti-cancer effects, and as a result, have found that Lactobacillus plantarum GB104 strain (Accession No.: KCTC 14107BP) exhibits excellent anti-cancer effects. Based on the above, the present inventors have completed the present invention. [Means for solving the problem]

[0008] In order to achieve the above-mentioned object, in one aspect of the present invention, there is provided a pharmaceutical composition for preventing or treating cancer, comprising Lactobacillus plantarum GB104 (L. plantarum GB104) strain (Accession No.: KCTC 14107BP) or a culture product thereof as an active ingredient.

[0009] In another aspect of the present invention, there is provided a food composition for preventing or inhibiting cancer, comprising Lactobacillus plantarum GB104 (L. plantarum GB104) strain (Accession Number: KCTC 14107BP) or a culture product thereof as an active ingredient.

[0010] In another aspect of the present invention, there is provided a feed composition for preventing or inhibiting cancer, comprising Lactobacillus plantarum GB104 (L. plantarum GB104) strain (Accession No.: KCTC 14107BP) or a culture product thereof as an active ingredient.

[0011] In another aspect of the present invention, there is provided a method for preventing or treating cancer, comprising administering Lactobacillus plantarum GB104 (L. plantarum GB104) strain (Accession No: KCTC 14107BP) or a culture product thereof to a non-human subject. Effect of the Invention

[0012] The Lactobacillus plantarum GB104 strain (Accession No.: KCTC 14107BP) according to the present invention increases the production of INF-γ and granzyme B, and activates immune cells such as cytotoxic T cells and NK cells in cancer cell lines or mouse models transplanted with cancer cell lines, thereby ultimately exhibiting an inhibitory effect on tumor formation and tumor growth. Therefore, the composition of the present invention containing the Lactobacillus plantarum GB104 strain as an active ingredient can be effectively used to prevent, improve or treat cancer diseases. [Brief description of the drawings]

[0013] [Figure 1]Illustrates the results obtained by checking the colony-forming ability after treatment with L. plantarum GB104 strain or common lactic acid bacteria 1 (L. fermentum GB102) in human colon cancer cell lines HCT116 and HT-29, respectively, where (-) is a group not treated with any strain as a negative control group. [Diagram 2] Graph showing colony formation ability in percentage (%) of the negative control group after treatment with L. plantarum strain GB104 or common Lactobacillus casei 1 (L. fermentum GB102) in human colon cancer cell lines HCT116 and HT-29, respectively. **P<0.01 [Diagram 3] The figures show the results obtained by checking the colony-forming ability of the human colon cancer cell lines HCT116 and HT-29, respectively, after treatment with a culture solution of L. plantarum strain GB104 or common lactic acid bacteria 1 (L. fermentum GB102). [Figure 4] Graph showing colony formation ability in percentage (%) of the negative control group after treatment with culture solution of L. plantarum GB104 strain or common lactic acid bacteria 1 (L. fermentum GB102) in human colon cancer cell lines HCT116 and HT-29, respectively. **P<0.01; ***P<0.001 [Diagram 5] This figure shows the experimental schedule for confirming the cancer preventive effect of common lactic acid bacteria 1 (L. fermentum GB102), common lactic acid bacteria 2 (L. fermentum GB103), or L. plantarum GB104 strains in a mouse-derived colon cancer CT-26 animal model. [Figure 6] Graph showing the results obtained by measuring the tumor size and growth rate after treatment with common lactic acid bacteria 1 (L. fermentum GB102), common lactic acid bacteria 2 (L. fermentum GB103) and L. plantarum GB104 strains, respectively, in a mouse-derived colon cancer CT-26 animal model. *P<0.05 [Figure 7]1 is a graph showing the results obtained by measuring the tumor size and growth rate of individual experimental animals from the negative control group and the group treated with L. plantarum strain GB104 in the mouse-derived colon cancer CT-26 animal model. [Figure 8] FIG. 1 shows an experimental schedule for confirming the anticancer activity of common lactic acid bacteria 3 (L. helveticus MG585) or L. plantarum GB104 strain in a mouse-derived colon cancer CT-26 animal model. [Figure 9] Graph showing the results obtained in a mouse-derived colon cancer CT-26 animal model by measuring tumor size and growth rate after treatment with three common lactic acid bacteria (L. helveticus MG585) and L. plantarum GB104 strains, respectively. **P<0.01 [Figure 10] 1 is a graph showing the results obtained by measuring the tumor size and growth rate of individual experimental animals from the negative control group and the group treated with L. plantarum strain GB104 in the mouse-derived colon cancer CT-26 animal model. [Figure 11] Graph (left) showing the results obtained by measuring tumor weight after treatment with L. plantarum GB104 strain in a mouse-derived colon cancer CT-26 animal model, and a photograph (right) showing tumor size compared to the negative control group. *P<0.05 [Figure 12] FIG. 1 shows an experimental schedule for confirming the anticancer activity of L. plantarum GB104 strain in a mouse-derived colon cancer MC-38 animal model. [Figure 13] Graph showing results obtained by measuring tumor size and growth rate after challenge with L. plantarum GB104 strain in a mouse-derived colon cancer MC-38 animal model. **P<0.01 [Figure 14] 1 is a graph showing the results obtained by measuring tumor weight after treatment with L. plantarum strain GB104 in a mouse-derived colon cancer MC-38 animal model. *P<0.05 [Figure 15]1 is a graph showing the results obtained by measuring the tumor size and growth rate of individual experimental animals from the negative control group and the group treated with L. plantarum GB104 strain in a mouse-derived colon cancer MC-38 animal model. [Figure 16] FIG. 1 shows an experimental schedule for confirming changes in immune cells in early-stage tumor tissues and peripheral blood after administration of L. plantarum GB104 strain in a mouse-derived colon cancer MC-38 animal model. [Figure 17] Graph showing results obtained by analyzing immune cell changes in early stage tumor tissues after treatment with L. plantarum strain GB104 in mouse-derived colon cancer MC-38 animal model. *P<0.05; ****P<0.0001 [Figure 18] Graph showing results obtained by analyzing immune cell changes in peripheral blood at early stages after treatment with L. plantarum strain GB104 in mouse-derived colon cancer MC-38 animal model. *P<0.05; **P<0.01; ***P<0.001 [Figure 19] FIG. 1 shows an experimental schedule for confirming changes in immune cells in late-stage tumor tissues after administration of common lactic acid bacteria 4 (L. plantarum GBCC_f0057) and L. plantarum GB104 strains, respectively, in a mouse-derived colon cancer MC-38 animal model. [Figure 20] Graph showing the results obtained by measuring the tumor size and growth rate after treatment with common lactic acid bacteria 4 (L. plantarum GBCC_f0057) and L. plantarum GB104 strains, respectively, in a mouse-derived colon cancer MC-38 animal model. *P<0.05 [Figure 21] 1 is a graph showing the results obtained by measuring the tumor size and growth rate of individual experimental animals from the negative control group and the group treated with L. plantarum GB104 strain in a mouse-derived colon cancer MC-38 animal model. [Figure 22]Graph showing the results obtained by analyzing immune cell changes in late stage tumor tissues after treatment with common Lactobacillus casei 4 (L. plantarum GBCC_f0057) and L. plantarum GB104 strains, respectively, in a mouse-derived colon cancer MC-38 animal model. *P<0.05; **P<0.01 DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0014] Pharmaceutical composition comprising L. plantarum strain GB104 or a culture product thereof In one aspect of the present invention, there is provided a pharmaceutical composition for preventing or treating cancer, comprising Lactobacillus plantarum GB104 (L. plantarum GB104) strain (Accession Number: KCTC 14107BP) or a culture product thereof as an active ingredient.

[0015] As used herein, the term "Lactobacillus" refers to aerobic or facultative anaerobic Gram-positive microorganisms of the genus Bacillus that are widely distributed in nature, and microorganisms belonging to the genus Lactobacillus include Lactobacillus plantarum, Lactobacillus sakei, etc.

[0016] As a result of research to develop a new strain with excellent anti-cancer effect, the present inventors selected Lactobacillus plantarum GB104 (L. plantarum GB104) as an anti-cancer candidate strain. The strain was deposited at the Korean Collection for Type Cultures, Korea Institute of Bioscience and Biotechnology, on January 14, 2020, under the accession number of KCTC 14107BP, and a patent application for the new strain was filed under Korean Patent Application No. 10-2020-0186738. The strain is a live strain, harmless to the human body, and can be used without side effects.

[0017] As used herein, the term "Lactobacillus plantarum GB104" may be interchangeably described as L. plantarum GB104, Lactobacillus plantarum GB104 or Lactobacillus plantarum strain GB104 (Accession Number: KCTC 14107BP).

[0018] The L. plantarum GB104 strain (Accession Number: KCTC 14107BP) is the same as that described above. In this case, the strain may be a viable cell, a dead cell, or a cytoplasmic fraction obtained by disrupting the strain, and the strain may preferably be a viable cell.

[0019] As used herein, the term "culture product" refers to a product obtained by culturing a live strain in a known medium, which may or may not contain the strain itself. The medium may be selected from known liquid or solid media. For example, the medium may be, but is not limited to, MRS liquid medium, GAM liquid medium, MRS agar medium, GAM agar medium, BL agar medium.

[0020] The composition contains, as an active ingredient, L. plantarum strain GB104 or a culture product thereof in a therapeutically effective amount or nutritionally effective concentration based on the total weight of the composition. 4 ~10 16 CFU / g, preferably 10 6 ~10 12 CFU / g of active ingredient or a culture product containing an equivalent number of viable cells. Generally, for adult patients, 1×10 6 CFU / g or more, preferably 1×10 8 ~1×10 12 The amount of viable cells in CFU / g may be administered in one or several divided doses.

[0021] The strains of the present invention are capable of inhibiting tumor formation. In addition, the strains activate immune cells.

[0022] As used herein, the term "immunity" refers to a mechanism that protects living organisms from disease by detecting and disabling pathogens and tumor cells in the organism. "Immunostimulation" can include a whole set of therapeutic or preventive strategies that enhance the body's defense mechanisms against various diseases, such as cancer and inflammation.

[0023] In one embodiment of the present invention, when colon cancer cell lines were treated with the strain or a culture solution from which the strain was removed, the formation of tumor cell colonies was significantly reduced compared to the negative control group (Figures 1-4). In addition, the degree of tumor formation by administering the strain from the time when the mouse-derived colon cancer cell line was subcutaneously implanted in the mouse was examined, and it was confirmed that the tumor formation was inhibited compared to the negative control group (Figures 5-7). In addition, the tumor growth by administering the L. plantarum GB104 strain to a tumor animal model in which a tumor of a certain size was formed was examined, and it was confirmed that the tumor growth rate was significantly reduced compared to the negative control group (Figures 8-22). In this case, the number of cytotoxic T cells and NK cells in the tumor tissue and blood was significantly increased, and the distribution of IFN-γ and granzyme B in immune cells was increased (Figures 17, 18 and 22). Through the above series of results, it was found that the strain had an immunostimulatory effect and an inhibitory effect on tumor formation and tumor growth.

[0024] Medicinal Use The pharmaceutical composition for preventing or treating cancer according to the present invention, which contains the L. plantarum GB104 strain or its culture product as an active ingredient, can increase the efficacy of treating and / or preventing cancer, wherein the L. plantarum GB104 strain and its culture product are the same as those described above.

[0025] The cancer may be selected from the group consisting of, but is not limited to, colon cancer, gastric cancer, liver cancer, lung cancer, breast cancer, prostate cancer, ovarian cancer, pancreatic cancer, cervical cancer, thyroid cancer, pharyngeal cancer, acute myeloid leukemia, brain tumor, neuroblastoma, retinoblastoma, head and neck cancer, salivary gland cancer, melanoma, bladder cancer, esophageal cancer, skin cancer, colorectal cancer and lymphoma.

[0026] In the pharmaceutical composition for preventing or treating cancer according to the present invention, the active ingredient may be contained in any amount (effective amount) depending on the use, formulation, purpose of incorporation, etc., as long as it can exhibit anti-cancer activity. Typically, the effective amount of L. plantarum GB104 strain is determined within the range of 0.001% by weight to 20.0% by weight based on the total weight of the composition. Here, the "effective amount" refers to the amount of active ingredient that can induce anti-cancer effect. Such an effective amount can be determined experimentally within the general skill of a person skilled in the art.

[0027] As used herein, the term "treatment" may be used to include both therapeutic and prophylactic treatment. In this case, prevention may be used to mean alleviating or reducing a pathology or disease in a subject. In one embodiment, the term "treatment" includes any form of administration or application to treat a disease in a mammal, including a human. In addition, the term "treatment" includes inhibiting or slowing the progression of a disease or disease, and includes restoring or repairing a damaged or lost function, thereby partially or completely relieving a disease, or stimulating an inefficient process, or relieving a severe disease.

[0028] As used herein, the term "efficacy" can be determined by one or more parameters, such as survival or disease-free survival over a certain period of time, such as 1 year, 5 years, or 10 years. In addition, the parameters can include inhibition of the size of at least one tumor in a subject.

[0029] Pharmacokinetic parameters such as bioavailability and basic parameters such as clearance rate can also affect efficacy. Thus, "enhanced efficacy" (e.g., improved efficacy) can be attributed to enhanced pharmacokinetic parameters and enhanced efficacy, and can be measured by comparing clearance rates and tumor growth in test animals or human subjects, or by comparing parameters such as survival time, recurrence rate, or disease-free survival.

[0030] Here, "therapeutically effective amount" or "pharmaceutical effective amount" refers to an amount of a compound or composition effective to prevent or treat a target disease, which is an amount sufficient to treat the disease with a reasonable benefit / risk ratio applicable to medical treatment and without causing side effects. The level of the effective amount can be determined depending on factors including the patient's health condition, the type and severity of the disease, the activity of the drug, sensitivity to the drug, the method of administration, the number of administrations, the route of administration and excretion rate, the duration of treatment, the drugs used in combination or in combination, and other factors well known in the medical field. In one embodiment, the therapeutically effective amount refers to an amount of a drug effective to treat cancer.

[0031] In this case, the pharmaceutical composition may further contain a pharma- ceutically acceptable carrier in addition to the active ingredient. Here, "pharma-ceutically acceptable" means that the applied (formulated) substance does not inhibit the activity of the active ingredient and does not show toxicity above a tolerable level. The pharma-ceutically acceptable carrier may be any carrier as long as it is a non-toxic material suitable for delivery to a patient. Distilled water, alcohol, lipids, waxes and inert solids may be included as carriers. In addition, pharmacologically acceptable adjuvants (buffers, dispersants) may be included in the pharmaceutical composition.

[0032] Specifically, the cryoprotectant may be at least one selected from the group consisting of glycerol, trehalose, maltodextrin, skim milk powder, and starch. In addition, the excipient may be at least one selected from the group consisting of glucose, dextrin, and skim milk powder.

[0033] The cryoprotectant may be contained in an amount of 0.01% to 20% by weight, or 0.01% to 10% by weight, based on the total weight of the composition. Specifically, the composition may contain glycerol in an amount of 5% to 20% by weight, trehalose in an amount of 2% to 10% by weight, maltodextrin in an amount of 2% to 10% by weight, skim milk powder in an amount of 0.5% to 2% by weight, and starch in an amount of 0.1% to 1% by weight. In addition, the excipient may be contained in an amount of 75% to 95% by weight, or 85% to 95% by weight, based on the total weight of the composition.

[0034] Carriers and diluents that may be included in the pharmaceutical composition may include gum acacia, alginates, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate and mineral oil.When formulated, it is prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrating agents and surfactants.

[0035] As long as the pharmaceutical composition according to the present invention shows the effect of the present invention, its dosage form, route of administration and method of administration are not particularly limited. The composition of the present invention can be administered to mammals, including humans, by any method. For example, it can be administered orally.

[0036] The pharmaceutical composition of the present invention may be formulated as a preparation for oral administration by the route of administration described above.In the case of preparation for oral administration, the composition of the present invention may be formulated into powder, granule, tablet, pill, dragee, capsule, liquid, gel, syrup, slurry, suspension, etc., by using the method known in the art.

[0037] When the pharmaceutical composition is prepared for oral administration, it may further comprise a carrier for oral administration.The carrier for oral administration may include lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, etc.Suitable stabilizers include antioxidants such as sodium hydrogen sulfite, sodium sulfite or ascorbic acid.Suitable preservatives include benzalkonium chloride, methyl or propyl paraben, and chlorobutanol.In addition to the above-mentioned components, the pharmaceutical composition of the present invention may further comprise anti-aggregating agents, lubricants, wetting agents, sweeteners, flavorings, emulsifiers, suspending agents, etc.

[0038] For example, the preparation for oral administration can be obtained by mixing active ingredient with solid excipient, pulverizing it, adding suitable auxiliary, and then processing it into a mixture of granules to obtain tablet or sugar-coated tablet.The example of suitable excipient can include sugar such as lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol and maltitol, starch such as corn starch, wheat starch, rice starch and potato starch, cellulose such as methylcellulose, sodium carboxymethylcellulose and hydroxypropylmethylcellulose, and filler such as gelatin and polyvinylpyrrolidone.In addition, crosslinked polyvinylpyrrolidone, agar, alginic acid or sodium alginate can be added as disintegrant if desired.

[0039] The pharmaceutical composition of the present invention may be administered in a pharmacologic effective amount. As used herein, the term "pharmacologic effective amount" refers to an amount sufficient to treat or prevent a disease with a reasonable benefit / risk ratio applicable to medical treatment or prevention. Effective dose level can be determined according to factors including the severity of the disease, the activity of the drug, the age, weight, health and sex of the patient, the sensitivity of the patient to the drug, the number of administrations of the composition of the present invention used, the route of administration and excretion rate, the duration of treatment, the drug used in combination with or in combination with the composition of the present invention used, and other factors well known in the medical field.

[0040] The preferred dosage of the pharmaceutical composition may range from 0.01 μg / kg to 10 g / kg, or from 0.01 mg / kg to 1 g / kg per day, depending on the patient's condition, weight, sex and age, severity of the disease, and route of administration. Administration can be once a day or in several divided doses. These dosages should not be construed as limiting the scope of the invention in any aspect.

[0041] The subjects to which the pharmaceutical composition may be applied (formulated) are mammals and humans, in particular the subject is preferably a human.

[0042] In addition to the active ingredient, the pharmaceutical composition of the present invention may further contain any compound or natural extract whose safety has already been verified and known to have anti-cancer activity, in order to increase or enhance anti-cancer activity.When the pharmaceutical composition of the present invention is administered in combination with other therapeutic agents, it may be administered consecutively or simultaneously with the conventional therapeutic agent.In addition, it may be administered in a single dose or multiple doses.Taking all the above factors into consideration, it is important to administer in the amount that can provide maximum effect in the minimum amount without side effects.

[0043] Food composition comprising L. plantarum GB104 strain or a culture product thereof In another aspect of the present invention, there is provided a food composition for preventing or inhibiting cancer, comprising Lactobacillus plantarum GB104 (L. plantarum GB104) strain (Accession Number: KCTC 14107BP) or a culture product thereof as an active ingredient.

[0044] The L. plantarum strain GB104 (accession number: KCTC 14107BP) was the same as that described above.

[0045] The food compositions for preventing or inhibiting cancer include all forms of functional foods, nutritional supplements, health foods and food additives, and this type of food composition can be prepared in various forms according to conventional methods known in the art.

[0046] When the L. plantarum strain GB104 or a culture product thereof is used as a food additive, the strain or culture product may be added as such or may be used together with other foods or food ingredients.

[0047] It can be used appropriately according to conventional methods. The mixed amount of active ingredients can be appropriately determined according to the purpose of use (prevention, health maintenance or therapeutic treatment). In general, it can be added to the raw material composition containing the strain when preparing food or beverage in an amount of 0.0001% by weight to 1% by weight, specifically 0.001% by weight to 0.1% by weight. However, in the case of long-term intake for health and hygiene purposes or health management purposes, an amount below the above range can also be used.

[0048] Feed composition comprising L. plantarum strain GB104 or a culture product thereof In another aspect of the present invention, there is provided a feed composition for preventing or inhibiting cancer, comprising Lactobacillus plantarum GB104 (L. plantarum GB104) strain (Accession No.: KCTC 14107BP) or a culture product thereof as an active ingredient.

[0049] The L. plantarum strain GB104 (accession number: KCTC 14107BP) was the same as that described above.

[0050] A feed composition for preventing or inhibiting cancer can be prepared by adding L. plantarum strain GB104 (Accession No.: KCTC 14107BP) or a culture product thereof in an appropriate effective concentration range according to various methods for preparing feed known in the art.

[0051] Use of a composition comprising L. plantarum strain GB104 or a culture product thereof In another embodiment of the present invention, there is provided a use of a pharmaceutical composition comprising L. plantarum strain GB104 or a culture product thereof for the treatment of cancer, wherein the L. plantarum strain GB104, the cancer and the treatment are the same as those described above.

[0052] In another aspect of the present invention, there is provided a use of a pharmaceutical composition comprising L. plantarum strain GB104 or a culture product thereof for enhancing therapeutic effect against cancer, wherein the L. plantarum strain GB104, the cancer and the treatment are the same as those described above.

[0053] In another aspect of the present invention, there is provided a method for treating cancer and / or enhancing a therapeutic effect, comprising administering to a subject Lactobacillus plantarum strain GB104 or a culture product thereof, wherein the L. plantarum strain GB104, the cancer and the treatment are the same as those described above.

[0054] The subject may be a subject suffering from cancer. Additionally, the subject may be a mammal, preferably a human.

[0055] The route of administration, dosage and frequency of administration of L. plantarum strain GB104 or its culture product may vary according to the patient's condition and the presence or absence of side effects, and therefore it may be administered to the subject in various ways and amounts.The optimal administration method, dosage and frequency of administration may be selected within an appropriate range by those skilled in the art.In addition, the above-mentioned active ingredient may be administered in combination with other drugs known to have a therapeutic effect on cancer (e.g., the anticancer drugs described above) or prophylactically active substances, or may be formulated in the form of a combined preparation with other drugs. EXAMPLES

[0056] Hereinafter, the present invention will be described in more detail by the following examples. However, the following examples are only for illustrating the present invention, and the scope of the present invention is not limited to these examples.

[0057] Example 1. Confirmation of the inhibitory effect on tumor formation by treatment with L. plantarum GB104 strain or its culture solution Using human colon cancer cell lines, the inhibitory effect on tumor formation was confirmed by treatment with L. plantarum GB104 strain (Accession Number: KCTC 14107BP) or its culture solution. For the culture supernatant of the strain (cell-free supernatant, CFS), the strain in the exponential (active) growth phase cultured in MRS medium for about 6 hours was harvested, and only the supernatant from which the strain was removed by centrifugation was obtained. The supernatant was prepared by filtering through a 0.22 μm filter.

[0058] Specifically, human colon cancer cell lines HCT116 and HT-29 were each diluted in 2 mL of McCoy's 5A medium, and then 1.5 × 10 cells were added. 3The cells were dispensed into 6-well cell culture plates at 1 × 10 cells / well and allowed to stabilize for 24 hours. After 24 hours, the medium was removed and treatments were performed with the respective samples together with fresh medium. Common Lactobacillus fermentum GB102 (Accession Number: KCTC14105BP) or L. plantarum GB104 strains were used as samples. Colon cancer cell lines were either treated directly with the strains (Figures 1 and 2) or with the strains in the form of culture supernatants (CFS) prepared by filtration (Figures 3 and 4). When cell lines were directly treated with the strains, treatments were performed at 1 × 10 cells / well. 7 In addition, when cell lines were treated with CFS, treatments were performed at a ratio of CFS to medium per well of 1:100 (20 μL / 2 mL).

[0059] The medium was replaced with fresh medium containing the strain or strain culture supernatant at intervals of 2 to 3 days and cultured for 10 days. The cultured plates were washed twice with DPBS and the cells were fixed with 4% formalin. The fixed cells were washed twice with DPBS and stained with 0.5% crystal violet solution for 5 minutes. The cells were then washed with distilled water and their colony-forming ability was confirmed.

[0060] As a result, it was confirmed that tumor formation in both human colon cancer cell lines HCT116 and HT-29 was significantly inhibited in the group treated with L. plantarum GB104 strain compared to the group treated with general Lactobacillus 1 when the cell lines were directly treated with the strain (Figures 1 and 2). In addition, it was confirmed that tumor formation was inhibited in the group treated with the culture solution of L. plantarum GB104 strain compared to the group treated with the culture solution of general Lactobacillus 1 even when the cell lines were treated with the strain culture supernatant (Figures 3 and 4). Through the above results, it was confirmed that L. plantarum GB104 strain was directly and indirectly involved in the inhibition of tumor formation.

[0061] Example 2. Confirmation of the cancer prevention effect of GB104 strain in an animal model: CT-26 model The cancer preventive effect of L. plantarum GB104 strain was confirmed using a mouse-derived colon cancer CT-26 animal model.

[0062] Six-week-old Balb / c mice (ORIENT BIO, Korea) were purchased and acclimated for one week. At 7 weeks of age, the area around the right flank of the mice was shaved, and then Balb / c mouse-derived colon cancer cell line CT-26 cells were inoculated at 5 × 10 cells per mouse. 5 The tumor animal model was established by subcutaneous injection at 100 μL per cell.

[0063] Common lactic acid bacteria 1 (L. fermentum GB102), common lactic acid bacteria 2 (L. fermentum GB103) (accession number: KCTC14106BP), or L. plantarum GB104 strain was administered daily at 1 × 10 9 The animals were orally administered with CFU / mouse (Figure 5). The tumor size was measured using a digital caliper, and the tumor volume was calculated using the following formula 1. [Formula 1] Tumor volume (mm 3 )=(minor axis(width) 2 × long axis (length) / 2

[0064] As a result, in the case of the group administered with common lactic acid bacteria 1 (L. fermentum GB102) or common lactic acid bacteria 2 (L. fermentum GB103), no significant difference in tumor growth rate was observed compared to the negative control group. On the other hand, in the case of the group administered with L. plantarum GB104 strain, it was confirmed that the tumor growth rate was significantly inhibited compared to the negative control group (control) (Figures 6 and 7). Through the above results, it was confirmed that administration with L. plantarum GB104 strain showed a tumor preventive effect against tumor formation.

[0065] Example 3. Confirmation of the cancer treatment effect of GB104 strain in an animal model: CT-26 model Using a mouse-derived colon cancer CT-26 animal model, the tumor treatment effect was confirmed by administration of L. plantarum GB104 strain.

[0066] The tumor animal model was established in the same manner as in Example 2, and the formed tumor was measured. On the fifth day after tumor cell injection, 3 Only mice with tumor sizes within the range were selected, and each group was randomly assigned. Common Lactobacillus helveticus MG585 (Accession Number: KCTC14110BP) or Lactobacillus plantarum GB104 strain was used as the sample, and 1 × 10 9 The cells were orally administered to an animal model at CFU / mouse (Figure 8).

[0067] As a result, in the group administered with common lactic acid bacteria 3 (L. helveticus MG585), no significant difference in tumor growth rate was observed compared to the negative control group. On the other hand, in the group administered with L. plantarum GB104, it was confirmed by measuring the tumor size and weight that the tumor growth rate was significantly inhibited compared to the negative control group (FIGS. 9-11). Through the above results, it was confirmed that administration of L. plantarum GB104 strain showed a tumor treatment effect after tumor formation.

[0068] Example 4. Confirmation of the cancer treatment effect of GB104 strain in an animal model: MC-38 model Using a mouse-derived colon cancer MC-38 animal model, the tumor treatment effect was confirmed by administration of L. plantarum GB104 strain.

[0069] Six-week-old C57BL / 6 mice (ORIENT BIO, Korea) were purchased and acclimated for one week. At 7 weeks of age, the area around the right flank of the mice was shaved, and then C57BL / 6 mouse-derived colon cancer cell line MC-38 cells were inoculated at 5 × 10 cells per mouse. 5 The tumor animal model was established by subcutaneous injection at 100 μL per cell. The tumor size was measured and calculated in the same manner as in Example 2.

[0070] On the fifth day after tumor cell injection, 30–50 mm 3Only mice with tumor sizes within the range of 1 × 10 were selected and randomized into groups. L. plantarum GB104 strain was administered daily at 1 × 10 9 The animals were orally administered with CFU / mouse (Figure 12).

[0071] As a result, it was confirmed by measuring the tumor size and weight that the tumor growth rate was significantly inhibited in the group administered with L. plantarum GB104 strain compared to the negative control group (FIGS. 13 to 15). Through the above results, it was confirmed that administration of L. plantarum GB104 strain showed a tumor treatment effect after tumor formation.

[0072] Example 5. Confirmation of changes in immune cells in early stage tumor tissues and peripheral blood after administration of GB104 strain: MC-38 model Using the mouse-derived colon cancer MC-38 animal model, we confirmed the changes in immune cells in early-stage tumor tissue and early-stage peripheral blood following treatment with L. plantarum strain GB104.

[0073] Specifically, the tumor model was prepared by incubating MC-38 cells, a colon cancer cell line derived from C57BL / 6 mice, at 2 × 10 cells per mouse. 5 The mice were then inoculated with 1×10 L. plantarum strain GB104 daily starting on day 7. 9 CFU / mouse were orally administered. Six days after the start of administration (day 13), tumor tissues and blood were collected from the mice, and immune cells were isolated (Figure 16). The isolated immune cells were stained with fluorescent antibodies that bind to the respective immune cell markers, and then analyzed using a FACSymphony instrument. The antibody information is shown in Table 1.

[0074] [Table 1]

[0075] As a result, in the case of immune cells in early stage tumor tissue, granzyme B secreted from NK cells was significantly increased in the group administered with L. plantarum GB104 strain compared to the negative control group. In addition, the ratio of regulatory T cells (Treg cells), which are known to inhibit tumor-specific immune responses and enable tumor immune evasion by establishing an immunosuppressive tumor microenvironment, was significantly reduced in the group administered with L. plantarum GB104 strain (Figure 17).

[0076] In the case of immune cells in peripheral blood, cytotoxic T cells (CD8 + The ratio of T cells and natural killer cells (NK cells) was significantly increased in the group administered with L. plantarum GB104 strain compared to the negative control group. In addition, IFN-γ secreted from these cells was also significantly increased. In addition, it was confirmed that M2 macrophages, which are known to support the growth of cancer cells, were significantly reduced in the group administered with L. plantarum GB104 strain (Figure 18).

[0077] Example 6. Confirmation of immune cell changes in late stage tumor tissues after treatment with GB104 strain: MC-38 model Using a mouse-derived colon cancer MC-38 animal model, we identified immune cell changes in late-stage tumor tissues upon challenge with L. plantarum strain GB104.

[0078] Specifically, the tumor model was established in the same manner as in Example 5, and the mice were inoculated with 1 × 10 9 CFU / mouse were orally administered. Thirteen days after administration (day 20), the study was terminated, tumor tissues were collected from the mice, and immune cells were isolated (FIG. 19). The isolated immune cells were stained with fluorescent antibodies in the same manner as in Example 5, and then analyzed using a FACSymphony instrument. The antibodies shown in Table 1 were used.

[0079] As a result, tumors of similar size to those in the negative control group were observed in the group administered with common lactic acid bacteria 4 (L. plantarum GBCC_f0057) compared to the negative control group, while the size of the tumors was significantly reduced in the group administered with L. plantarum GB104 strain compared to the negative control group (Figures 20 and 21).

[0080] In addition, cytotoxic T cells (CD8 + It was confirmed that the number of T cells (immune T cells) and natural killer cells (NK cells) was significantly increased in the group administered L. plantarum GB104 strain compared to the tumor tissue collected from the negative control group. In addition, it was confirmed that IFN-γ and granzyme B secreted from these cells were also significantly increased. On the other hand, it was confirmed that the group administered common lactic acid bacteria 4 (L. plantarum GBCC_f0057) showed similar results to those of the negative control group (Figure 22).

[0081] Through the above results, we confirmed that the number of immune cells involved in anti-tumor immunity was increased by administration of L. plantarum GB104 strain, and that the changes in immune cells were associated with anti-cancer activity. [Accession number]

[0082] Name of depository institution: Korean Collection for Type Cultures (KCTC), Korea Institute of Bioscience and Biotechnology Accession number: KCTC14107BP Deposit date: January 14, 2020

Claims

1. A pharmaceutical composition for preventing or treating cancer, comprising Lactobacillus plantarum GB104 (L. plantarum GB104) strain (Accession Number: KCTC 14107BP) or a culture product thereof as an active ingredient.

2. The pharmaceutical composition for preventing or treating cancer according to claim 1 , wherein the strain or a culture product thereof exhibits an inhibitory effect on tumor formation.

3. The pharmaceutical composition for preventing or treating cancer according to claim 1 , wherein the strain exhibits an immunostimulatory effect.

4. 2. The pharmaceutical composition for preventing or treating cancer according to claim 1, wherein the cancer is any one selected from the group consisting of colon cancer, gastric cancer, liver cancer, lung cancer, breast cancer, prostate cancer, ovarian cancer, pancreatic cancer, cervical cancer, thyroid cancer, pharyngeal cancer, acute myeloid leukemia, brain tumor, neuroblastoma, retinoblastoma, head and neck cancer, salivary gland cancer, melanoma, bladder cancer, esophageal cancer, skin cancer, colorectal cancer and lymphoma.

5. A food composition for preventing or inhibiting cancer, comprising Lactobacillus plantarum GB104 (L. plantarum GB104) strain (Accession Number: KCTC 14107BP) or a culture product thereof as an active ingredient.

6. A feed composition for preventing or inhibiting cancer, comprising Lactobacillus plantarum GB104 (L. plantarum GB104) strain (Accession No.: KCTC 14107BP) or a culture product thereof as an active ingredient.

7. 1. A method for preventing or treating cancer, comprising administering Lactobacillus plantarum GB104 (L. plantarum GB104) strain (Accession Number: KCTC 14107BP) or a culture product thereof to a non-human subject.

Citation Information

Patent Citations

  • Tumor cytotoxic agents and methods thereof

    JP2014500263A